The Food and Drug Administration on Friday approved medicines from Eli Lilly and Italy’s Menarini Group for a type of advanced lymphoma and a specific kind of metastatic breast cancer, respectively.
The two drugs join a long list of new cancer therapies cleared by the FDA, which over the past five years has granted approvals to more than six dozen treatments for a wide array of malignancies.
